Keith J Ou, Jingjie Du, Guanchen Liu, Arjun Chapagain, Daniel A Nuccio, Pallavi Singh, Woo Kyun Kim, Young Min Kwon, Xin Gen Lei
{"title":"Efficacy and Biosafety of 25-Hydroxyvitamin D<sub>3</sub> Biofortified in Egg Yolk in Mice Fed Two Levels of Dietary Fat.","authors":"Keith J Ou, Jingjie Du, Guanchen Liu, Arjun Chapagain, Daniel A Nuccio, Pallavi Singh, Woo Kyun Kim, Young Min Kwon, Xin Gen Lei","doi":"10.1016/j.tjnut.2025.06.011","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vitamin D inadequacy remains a public health concern, particularly in individuals with obesity. Biofortified eggs with 25-hydroxyvitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] may increase intakes of the active metabolite of this nutrient by the public.</p><p><strong>Objectives: </strong>This study determined efficacy, biosafety, and gut microbiome impact of 25(OH)D<sub>3</sub> biofortified in egg yolk compared with a synthetic form in mice fed a control or high-fat diet (HFD).</p><p><strong>Methods: </strong>Reg3b<sup>+/-</sup> mice (n = 4 males + 4 females/group, 3-5 mo old) were fed a control (CON) or HFD (12% or 60% kcal from fat) supplemented (per kg of diet) with 200 international unit (IU) of 25(OH)D<sub>3</sub> from the control yolk (BAS), the BAS + 500 IU of 25(OH)D<sub>3</sub> from the synthetic form (SUP), or 700 IU of 25(OH)D<sub>3</sub> from the biofortified yolk (YOL) for 8 wk. Body weight, plasma concentrations of 25(OH)D<sub>3</sub>, osteocalcin, and receptor activator of nuclear factor kappa β ligand, bone microtomography, bone-related genes and proteins, and colonic and fecal microbiome were examined. Data were analyzed by 2-way analysis of variance.</p><p><strong>Results: </strong>The HFD-YOL group had 33.4% (P < 0.01) and 39.2% (P < 0.001) higher plasma 25(OH)D<sub>3</sub> concentrations at week 8 than the HFD-SUP and CON-YOL groups, respectively. This elevation was associated with upregulated kidney mRNA levels of cytochrome P450 24A1 (Cyp24a1) and vitamin D receptor (Vdr). Both sources of 25(OH)D<sub>3</sub> unaltered body weights, blood glucose concentration, plasma alkaline phosphatase activity, plasma osteocalcin concentrations, or bone characteristics but altered (P < 0.05) fecal microbiome compositions.</p><p><strong>Conclusions: </strong>Compared with the synthetic form, 25(OH)D<sub>3</sub> in the biofortified yolk led to higher plasma 25(OH)D<sub>3</sub> concentrations in mice-fed HFD. However, such efficacy in mice fed CON and impacts on fecal microbiome were similar between the 2 sources of 25(OH)D<sub>3</sub>. Our finding suggests biosafety and nutritional relevance for future human study of this novel food source of 25(OH)D<sub>3</sub>.</p>","PeriodicalId":16620,"journal":{"name":"Journal of Nutrition","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nutrition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tjnut.2025.06.011","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Vitamin D inadequacy remains a public health concern, particularly in individuals with obesity. Biofortified eggs with 25-hydroxyvitamin D3 [25(OH)D3] may increase intakes of the active metabolite of this nutrient by the public.
Objectives: This study determined efficacy, biosafety, and gut microbiome impact of 25(OH)D3 biofortified in egg yolk compared with a synthetic form in mice fed a control or high-fat diet (HFD).
Methods: Reg3b+/- mice (n = 4 males + 4 females/group, 3-5 mo old) were fed a control (CON) or HFD (12% or 60% kcal from fat) supplemented (per kg of diet) with 200 international unit (IU) of 25(OH)D3 from the control yolk (BAS), the BAS + 500 IU of 25(OH)D3 from the synthetic form (SUP), or 700 IU of 25(OH)D3 from the biofortified yolk (YOL) for 8 wk. Body weight, plasma concentrations of 25(OH)D3, osteocalcin, and receptor activator of nuclear factor kappa β ligand, bone microtomography, bone-related genes and proteins, and colonic and fecal microbiome were examined. Data were analyzed by 2-way analysis of variance.
Results: The HFD-YOL group had 33.4% (P < 0.01) and 39.2% (P < 0.001) higher plasma 25(OH)D3 concentrations at week 8 than the HFD-SUP and CON-YOL groups, respectively. This elevation was associated with upregulated kidney mRNA levels of cytochrome P450 24A1 (Cyp24a1) and vitamin D receptor (Vdr). Both sources of 25(OH)D3 unaltered body weights, blood glucose concentration, plasma alkaline phosphatase activity, plasma osteocalcin concentrations, or bone characteristics but altered (P < 0.05) fecal microbiome compositions.
Conclusions: Compared with the synthetic form, 25(OH)D3 in the biofortified yolk led to higher plasma 25(OH)D3 concentrations in mice-fed HFD. However, such efficacy in mice fed CON and impacts on fecal microbiome were similar between the 2 sources of 25(OH)D3. Our finding suggests biosafety and nutritional relevance for future human study of this novel food source of 25(OH)D3.
期刊介绍:
The Journal of Nutrition (JN/J Nutr) publishes peer-reviewed original research papers covering all aspects of experimental nutrition in humans and other animal species; special articles such as reviews and biographies of prominent nutrition scientists; and issues, opinions, and commentaries on controversial issues in nutrition. Supplements are frequently published to provide extended discussion of topics of special interest.